Arcus Biosciences, Inc. (RCUS) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
RCUS currently has 125M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 42.11% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 05, 2026 |
10-Q filing | 125.4M shares outstanding |
130M | 0 |
| Oct 28, 2025 |
10-Q filing | 106.5M shares outstanding |
110M | 0 |
| Aug 06, 2025 |
10-Q filing | 106.5M shares outstanding |
110M | 0 |
| May 06, 2025 |
10-Q filing | 98.4M shares outstanding |
98M | 0 |
| Feb 25, 2025 |
10-K filing | 105.8M shares outstanding |
110M | 0 |
| Nov 06, 2024 |
10-Q filing | 91.4M shares outstanding |
91M | 0 |
| Aug 08, 2024 |
10-Q filing | 91.1M shares outstanding |
91M | 0 |
| May 08, 2024 |
10-Q filing | 86.2M shares outstanding |
86M | 0 |
| Feb 21, 2024 |
10-K filing | 90.9M shares outstanding |
91M | 0 |
| Jan 30, 2024 |
8-K filing: Arcus Biosciences, Inc. and Gilead Sciences, Inc. entered into a Third Amended and Restated Common Stock Purchase Agreement, under which Gilead purchased 15,238,095 shares of Arcus's common stock at $21.00 per share. ($320.0M proceeds) |
75M | 0 |
| Nov 07, 2023 |
10-Q filing | 74.6M shares outstanding |
75M | 0 |
| Aug 07, 2023 |
10-Q filing | 73.2M shares outstanding |
73M | 0 |
| Jun 28, 2023 |
8-K filing: Arcus Biosciences, Inc. and Gilead Sciences, Inc. entered into a Second Amended and Restated Common Stock Purchase Agreement, where Gilead will purchase from Arcus 1,010,000 shares of Arcus common stock at a purchase price of $19.26 per share. ($19.45M proceeds) |
73M | 0 |
| May 09, 2023 |
10-Q filing | 73.0M shares outstanding |
73M | 0 |
| Feb 28, 2023 |
10-K filing | 72.0M shares outstanding |
72M | 0 |
| Nov 02, 2022 |
10-Q filing | 72.2M shares outstanding |
72M | 0 |
| Aug 03, 2022 |
10-Q filing | 72.2M shares outstanding |
72M | 0 |
| May 09, 2022 |
10-Q filing | 71.7M shares outstanding |
72M | 0 |
| Feb 23, 2022 |
10-K filing | 69.3M shares outstanding |
69M | 0 |
| Nov 08, 2021 |
10-Q filing | 70.1M shares outstanding |
70M | 0 |
| Aug 05, 2021 |
10-Q filing | 71.4M shares outstanding |
71M | 0 |
| May 05, 2021 |
10-Q filing | 71.0M shares outstanding |
71M | 0 |
| Feb 25, 2021 |
10-K filing | 70.9M shares outstanding |
71M | 0 |
| Nov 05, 2020 |
10-Q filing | 65.1M shares outstanding |
65M | 0 |
| Aug 06, 2020 |
10-Q filing | 64.9M shares outstanding |
65M | 0 |
| Jul 13, 2020 |
8-K filing: On July 13, 2020, Arcus and Gilead closed the Option, License and Collaboration Agreement, Common Stock Purchase Agreement and Investor Rights Agreement. Gilead purchased 5,963,029 shares of Arcus common stock at $33.54 per share, totaling approximately $200 million. ($200.0M proceeds) |
46M | 0 |
| May 26, 2020 |
8-K filing: Arcus Biosciences, Inc. appointed David L. Lacey, M.D. to the Board of Directors as a Class II Director and approved an amendment to the Company's Amended and Restated Bylaws to implement a forum selection bylaw. Arcus is also refiling its Amended and Restated Investor Rights Agreement. |
46M | 0 |
| May 05, 2020 |
10-Q filing | 46.0M shares outstanding |
46M | 0 |
| Mar 05, 2020 |
10-K filing | 45.4M shares outstanding |
45M | 0 |